AARTIPHARM

Aarti Pharmalabs Limited

CDMO for APIs, intermediates and small molecules including HPAPI and oncology blocks

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

aartipharmalabs.com(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-10-16

Stock price
₹873.65
Market cap
7,919 Cr
Stock P/E
37.3
P/B
3.73
Dividend yield
0.5%
ROE (FY26)
8.1%
ROCE (FY26)
10.0%
Operating margin (FY26)
14.6%
Debt / equity (FY26)
0.32
OCF / EBITDA (FY26)
70.9%
OCF / EBITDA (3Y)
66.4%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Aarti Pharmalabs makes xanthine derivatives such as caffeine and theophylline, active pharmaceutical ingredients (APIs) and intermediates, and does contract development and manufacturing (CDMO/CMO) for drug companies, selling mostly to customers outside India.

Company snapshot

49thBy market cap

Ranked among 119 companies in Pharmaceuticals.

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales440 Cr449 Cr506 Cr555 Cr458 Cr538 Cr564 Cr386 Cr418 Cr432 Cr583 Cr536 Cr
Operating expenses (approx.)352 Cr353 Cr388 Cr459 Cr364 Cr409 Cr418 Cr291 Cr344 Cr330 Cr470 Cr400 Cr
EBITDA88 Cr96 Cr118 Cr96 Cr94 Cr129 Cr146 Cr95 Cr75 Cr102 Cr113 Cr136 Cr
OPM %20.0%21.3%23.2%17.4%20.5%23.9%25.8%24.7%17.9%23.7%19.4%25.4%
Other income0.98 Cr1 Cr2 Cr2 Cr4 Cr5 Cr-2 Cr2 Cr0.05 Cr-0.37 Cr8 Cr0.45 Cr
Interest4 Cr4 Cr5 Cr5 Cr6 Cr10 Cr7 Cr7 Cr11 Cr13 Cr17 Cr13 Cr
Depreciation18 Cr19 Cr19 Cr20 Cr21 Cr23 Cr23 Cr23 Cr25 Cr29 Cr28 Cr30 Cr
Profit before tax67 Cr74 Cr96 Cr74 Cr72 Cr101 Cr115 Cr65 Cr39 Cr63 Cr82 Cr101 Cr
Tax %22.6%28.5%31.9%24.7%23.9%26.5%22.9%24.4%27.8%23.7%25.2%24.7%
Net profit52 Cr53 Cr65 Cr55 Cr55 Cr74 Cr88 Cr50 Cr28 Cr48 Cr61 Cr76 Cr
EPS (₹)₹5.72₹5.82₹7.20₹6.12₹6.03₹8.16₹9.75₹5.46₹3.08₹5.29₹6.74₹8.40

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2023Mar 2024Mar 2025Mar 2026TTM
Sales1,945 Cr1,853 Cr2,115 Cr1,819 CrSign in free for the trailing twelve months
Operating expenses (approx.)1,603 Cr1,467 Cr1,651 Cr1,450 CrSign in free for the trailing twelve months
EBITDA342 Cr386 Cr464 Cr369 CrSign in free for the trailing twelve months
OPM %17.6%20.8%22.0%20.3%Sign in free for the trailing twelve months
Other income2 Cr5 Cr10 Cr10 CrSign in free for the trailing twelve months
Interest21 Cr17 Cr27 Cr47 CrSign in free for the trailing twelve months
Depreciation63 Cr73 Cr87 Cr104 CrSign in free for the trailing twelve months
Profit before tax261 Cr300 Cr361 Cr233 CrSign in free for the trailing twelve months
Tax %25.8%27.8%24.5%25.0%Sign in free for the trailing twelve months
Net profit193 Cr217 Cr272 Cr175 CrSign in free for the trailing twelve months
EPS (₹)₹21.35₹23.93₹30.06₹19.27Sign in free for the trailing twelve months
Dividend payout %0.0%8.4%11.6%20.8%Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2023Mar 2024Mar 2025Mar 2026
Equity capital45 Cr45 Cr45 Cr45 Cr
Reserves1,513 Cr1,712 Cr1,945 Cr2,079 Cr
Borrowings214 Cr264 Cr396 Cr686 Cr
Other liabilities458 Cr561 Cr520 Cr671 Cr
Total liabilities2,231 Cr2,582 Cr2,906 Cr3,482 Cr
Fixed assets (net)923 Cr1,015 Cr1,104 Cr1,336 Cr
CWIP62 Cr78 Cr307 Cr305 Cr
Investments74 Cr107 Cr77 Cr259 Cr
Loans & advances7 Cr1 Cr1 Cr0.50 Cr
Inventories602 Cr643 Cr588 Cr640 Cr
Trade receivables440 Cr519 Cr575 Cr583 Cr
Cash & bank25 Cr24 Cr7 Cr9 Cr
Other assets98 Cr195 Cr248 Cr349 Cr
Total assets2,231 Cr2,582 Cr2,906 Cr3,482 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity263 Cr216 Cr332 Cr262 Cr
Cash from investing-158 Cr-215 Cr-414 Cr-431 Cr
Cash from financing-163 Cr10 Cr65 Cr171 Cr
Net cash flow-58 Cr12 Cr-17 Cr2 Cr
Free cash flow (OCF − Capex)143 Cr18 Cr-112 Cr-186 Cr

Ratios

MetricMar 2023Mar 2024Mar 2025Mar 2026
ROCE %15.9%15.7%16.2%10.0%
ROE %12.4%12.3%13.7%8.1%
Debtor days8210299117
Inventory days216273241281
Days payable124161114147
Cash conversion cycle174215226251
OCF / EBITDA %76.9%56.0%71.4%70.9%
OCF / EBITDA % (3 years)——68.0%66.4%
Debt / equity0.140.150.200.32
Current ratio1.951.942.011.49
Net debt / EBITDA0.550.620.841.83